No one should have to go through the ordeal of seeing intimate deepfakes of themselves online. We will not allow the proliferation of these demeaning and degrading images, which are disproportionately aimed at women and girls.

The Government will legislate in the Crime and Policing Bill – which is currently in Parliament – to ban nudification tools. This new criminal offence will make it illegal for companies to supply tools and services designed to create non-consensual intimate images, targeting the problem at its source.

The real-world testing of WYSA, which is one of the projects for the AI in Health and Care Award, finished in August 2023. The results are being independently evaluated by a Technology Specific Evaluation team from iCAIRD and are expected to be published early 2024.

Evaluations of AI in Health and Care projects will fill key evidence gaps for relevant published evidence standards frameworks and focus on accuracy, safety, effectiveness, value, fit with site, implementation, feasibility of scale up and sustainability of scale up.

The National Institute for Health and Care Excellence (NICE) Early Value Assessments are specifically looking at promising technologies with an emerging evidence base for clinical effectiveness, including apps for use within mental health treatment as one of its pilot topics. NICE has released guidance for guided digital Cognitive Behavioural Therapy tools for children and young people with symptoms of low mood and anxiety, which conditionally recommends these products for use once they have generated further evidence and achieved the NHS England Digital Technology Assessment Criteria. NICE have also recently launched a consultation on guidance for digital technologies to support adults with depression or anxiety, to gather views before a conditional recommendation is made.

The draft guidance for these products has been produced through the National Institute for Health and Care Excellence’s (NICE) Early Value Assessment pilot process. NICE’s conditional recommendation will support further evidence generation, assessing clinical and cost effectiveness until the product meets the requirements for evidence to receive full guidance. The full guidance will determine efficacy in comparison to other treatments options, including in-person cognitive behavioural therapy.

The products are conditionally recommended as a first-line treatment option or alongside other treatments for children and young people. The conditional recommendation and accompanying points on evidence generation may change after consultation. Until full guidance is confirmed post consultation, there is no estimate to determine the number of prescriptions expected to be made.

The draft guidance for these products has been produced through the National Institute for Health and Care Excellence’s (NICE) Early Value Assessment pilot process. NICE’s conditional recommendation will support further evidence generation, assessing clinical and cost effectiveness until the product meets the requirements for evidence to receive full guidance. The full guidance will determine efficacy in comparison to other treatments options, including in-person cognitive behavioural therapy.

The products are conditionally recommended as a first-line treatment option or alongside other treatments for children and young people. The conditional recommendation and accompanying points on evidence generation may change after consultation. Until full guidance is confirmed post consultation, there is no estimate to determine the number of prescriptions expected to be made.

The draft guidance for these products has been produced through the National Institute for Health and Care Excellence’s (NICE) Early Value Assessment pilot process. NICE’s conditional recommendation will support further evidence generation, assessing clinical and cost effectiveness until the product meets the requirements for evidence to receive full guidance. The full guidance will determine efficacy in comparison to other treatments options, including in-person cognitive behavioural therapy.

The products are conditionally recommended as a first-line treatment option or alongside other treatments for children and young people. The conditional recommendation and accompanying points on evidence generation may change after consultation. Until full guidance is confirmed post consultation, there is no estimate to determine the number of prescriptions expected to be made.

As of 17 February 2021 1,764,520 contact tracing alerts have been sent out to app users in England who have been in close contact with someone who has tested positive for coronavirus.

Users of the NHS COVID-19 app are anonymous. Therefore, we do not hold data on the number of contact tracing alerts by employment sector.

We identified that 15,841 cases between 25 September and 2 October were not included in the reported daily COVID-19 cases.

While there was a delay in reporting these positive test results in the public data, and in transferring them to the contact tracing system, anybody testing positive received their results in the normal way, and in the normal timeframe. All outstanding cases were immediately transferred to the contact tracing system by 1am on 3 October.

While there was a delay in reporting these positive test results in the public data, and in transferring them to the contact tracing system, anybody testing positive received their results in the normal way, and in the normal timeframe. All outstanding cases were immediately transferred to the contact tracing system by 1am on 3 October.